news
Plasma-based engineering to accelerate antimicrobial material development
Could plasma-based engineering provide a greener method to produce antimicrobial materials, such as contact-killing, antifouling and drug-release surfaces?
List view / Grid view
Staphylococcus aureus (S. aureus)
news
Infrared thermography can detect pre-visual bacterial growth, shows study
A new paper shows thermal imaging (infrared thermography) can detect E. coli and S. aureus bacteria after just six hours of incubation, long before it is visible to the human eye.
news
Novel antibiotic shows promise in Phase II C. difficile study
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
article
Antibiotics: resist the resistance
15 September 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…
news
FDA approves label update for Teflaro
2 September 2015 | By Victoria White
Teflaro is now approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia...
news
Aridis expands Phase 2a trial of AR-301 into the US
9 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)...
news
Pfizer begins Phase 2b study of S. aureus vaccine in adults undergoing elective spinal fusion surgery
7 July 2015 | By Victoria White
The first patients have been enrolled in a Phase 2b clinical trial of Pfizer’s S. aureus vaccine in adults undergoing elective spinal fusion surgery...
news
Nabriva Therapeutics presents data on lefamulin at ECCMID 2015
27 April 2015 | By Victoria White
Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015...
news
Changing the way we combat bacterial infections: Dutch biotech Micreos launches first bacteria-killing enzyme for human use against MRSA
5 November 2014 | By Micreos
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)...
news
Merck receives approval to market GARDASIL®, ZOLINZA® and CUBICIN®
1 July 2011 | By Merck
Merck announced that the Japanese MHLW approved three products – GARDASIL®, ZOLINZA® and CUBICIN®...
news
Merck and Intercell terminate Phase II/III clinical trial of V710
8 June 2011 | By Merck
DMC recommends termination of the evaluation of investigational Staphylococcus aureus vaccine, V710...
news
Update on Phase II/III clinical trial of investigational staphylococcus aureus vaccine, V710
11 April 2011 | By Merck
After a pre-specified interim analysis the DMC has recommended suspension of enrollment...
